应用PlanIQ™比较左侧乳腺癌放疗中屏气与自由呼吸照射
这项回顾性研究纳入35例接受左侧乳腺三维放疗深度吸气屏气治疗的患者,比较屏气与自由呼吸可行性剂量体积直方图及屏气临床计划与屏气可行性剂量体积直方图。结果显示30例患者屏气治疗心脏平均剂量及V5Gy、V20Gy显著降低,左肺仅V5Gy显著降低;结论认为PlanIQ™可作为自由呼吸与屏气治疗决策支持工具,实现个体化技术选择。
要点
- 30例患者屏气治疗较自由呼吸心脏平均剂量降低35.7%,V5Gy降低54.5%,V20Gy降低2.1%。
- 左肺仅V5Gy显著降低21.4%(p=0.046)。
- 5例患者心脏与肺可行性剂量体积直方图 cutoff 点差异小于1%。
核心结论
- 使用PlanIQ™作为自由呼吸与屏气治疗实施方式的决策支持工具,可利用最适合每位患者的技术实现治疗个体化,从而准确管理可用技术。
研究设计与样本
- 回顾性研究纳入35例接受左侧乳腺三维放疗深度吸气屏气治疗的患者。
- 每例患者采集自由呼吸与屏气CT扫描,由经验丰富的放射肿瘤学家在两种影像数据集上勾画靶区,危及器官使用自动分割软件勾画后导出至PlanIQ™生成可行性剂量体积直方图。
- 比较屏气与自由呼吸可行性剂量体积直方图的剂量学参数,以及屏气临床数据集与屏气可行性剂量体积直方图。
主要发现
- 35例中30例患者屏气治疗心脏平均剂量显著降低(p<0.05),降低35.7%;心脏V5Gy降低54.5%,V20Gy降低2.1%。
- 左肺降低幅度较小,仅V5Gy显著降低21.4%(p=0.046)。
- 其余5例患者心脏与肺可行性剂量体积直方图 cutoff 点重叠,差异小于1%。
- 屏气临床计划的心脏与左肺剂量学参数位于可行性剂量体积直方图的困难区,与界定不可行区与可行区之间缓冲区的可行性剂量体积直方图曲线对应参数显著不同(p<0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer is the most widespread cancer in women and young women worldwide. Moving towards customised radiotherapy, balancing the use of the available technology with the best treatment modality may not be an easy task in the daily routine. This study aims to evaluate the effectiveness of introducing IQ-feasibility into clinical practice to support the decision of free-breathing (FB) versus breath-hold (BH) left-sided breast irradiations, in order to optimise the technology available and the effectiveness of the treatment. METHODS: Thirty-five patients who received 3D radiotherapy treatment of the left breast in deep-inspiration BH were included in this retrospective study. Computed tomography scans in FB and BH were acquired for each patient; targets contoured in both imaging datasets by an experienced radiation oncologist, and organs at risk delineated using automatic segmentation software were exported to PlanIQ™ (Sun Nuclear Corp.) to generate feasibility dose volume histogram (FDVHs). The dosimetric parameter of BH versus FB FDVH, and BH clinical dataset versus BH FDVH were compared. RESULTS: A total of 30 patients out of 35 patients analysed, presented for the BH treatments a significant reduction (p < 0.05) in the heart mean dose ([Formula: see text]), volume receiving 5 Gy ([Formula: see text]) and 20 Gy ([Formula: see text]), of 35.7%, 54.5%, and 2.1%, respectively; for the left lung, a lower reduction was registered and significant only for [Formula: see text] (21.4%, p = 0.046). For the remaining five patients, the FDVH cut-off points of heart and lung were superimposable with differences of less than 1%. Heart and left lung dosimetric parameters of the BH clinical plans are located in the difficult zone of the FDVH and differ significantly (p < 0.05) from the corresponding parameters of the FDVH curves delimiting this buffer area between the impossible and feasible zones, respectively. CONCLUSION: The use of PlanIQTM as a decision-support tool for the FB versus BH treatment delivery modality allows customisation of the treatment technique using the most appropriate technology for each patient enabling accurate management of available technologies.
引用
- Yuan K, Yao X, Liao X, et al. Comparing breath hold versus free breathing irradiation for left-sided breast radiotherapy by PlanIQ™. Radiat Oncol. 2023. PMID: 38098106. doi:10.1186/s13014-023-02386-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。